Literature DB >> 19844741

Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas.

Jinzhong Liu1, Gaofeng Lu, Fuai Tang, Yiqing Liu, Guanglin Cui.   

Abstract

Immunosuppressive factors derived from the tumor and nontumor cells present in the tumor microenvironment contribute to tumor escape from host immune attack. Recently, the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) derived from both the tumor cells and surrounding nontumor cells was found to function as a critical immunosuppressive factor. While the expression of IDO is intensively under investigation in many types of cancers, little information is available in esophageal squamous cell carcinomas (ESCC) thus far. In this study, we have therefore investigated the cellular localization of IDO in 45 ESSCs and ten morphologically normal esophageal tissues; the correlation of IDO with clinicopathological parameters was also analyzed. Immunohistochemistry (IHC) analysis revealed that the density of IDO-positive cells was increased in ESCCs relative to controls (P < 0.01). These cells were distributed as clusters and formed a patchy pattern in both the cancerous epithelium and the surrounding noncancerous cells. Double IHC further confirmed that many IDO-positive cells in the tumor stroma were smooth-muscle-actin-alpha-positive myofibroblasts, CD68-positive macrophages, and S100-positive dendritic cells. Statistical analysis showed that the densities of IDO-positive cells were not significantly correlated with tumor clinical parameters (tumor invasion depth, node metastasis, and TNM stages) and lymphocytic infiltration. Our current findings suggested that the increased IDO expression in ESCCs is from a mixed cellular source (both cancer cells and noncancerous cells). Further studies on immune cell functional analysis are required in the future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844741     DOI: 10.1007/s00428-009-0846-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  45 in total

Review 1.  Indoleamine 2,3-dioxygenase in immune suppression and cancer.

Authors:  Alexander J Muller; George C Prendergast
Journal:  Curr Cancer Drug Targets       Date:  2007-02       Impact factor: 3.428

2.  [Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma].

Authors:  Kenichi Sakurai; Katsuhisa Enomoto; Sadao Amano; Tomo Kimura; Kiminobu Sugito; Kei Kimizuka; Taro Ikeda; Masahiko Shibata; Nanao Negishi
Journal:  Gan To Kagaku Ryoho       Date:  2004-10

3.  Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum.

Authors:  Guanglin Cui; Rasmus Goll; Trine Olsen; Sonja Eriksson Steigen; Anne Husebekk; Barthold Vonen; Jon Florholmen
Journal:  Cancer Immunol Immunother       Date:  2006-12-08       Impact factor: 6.968

Review 4.  Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.

Authors:  Diego O Croci; Mariano F Zacarías Fluck; María J Rico; Pablo Matar; Gabriel A Rabinovich; O Graciela Scharovsky
Journal:  Cancer Immunol Immunother       Date:  2007-06-15       Impact factor: 6.968

5.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

6.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Authors:  Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

7.  Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix.

Authors:  Peter Sedlmayr; Michaela Semlitsch; Girmai Gebru; Eva Karpf; Olaf Reich; Tao Tang; Reinhold Wintersteiger; Osamu Takikawa; Gottfried Dohr
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

8.  Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.

Authors:  Ke Pan; Hui Wang; Min-shan Chen; Hua-kun Zhang; De-sheng Weng; Jun Zhou; Wei Huang; Jian-jun Li; Hai-feng Song; Jian-chuan Xia
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-26       Impact factor: 4.553

Review 9.  Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

Authors:  Maria Zamanakou; Anastasios E Germenis; Vaios Karanikas
Journal:  Immunol Lett       Date:  2007-07-02       Impact factor: 3.685

10.  Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer.

Authors:  Duane H Hamilton; Peter A Bretscher
Journal:  Cancer Immunol Immunother       Date:  2008-01-10       Impact factor: 6.968

View more
  12 in total

Review 1.  Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.

Authors:  Srikanth Santhanam; David M Alvarado; Matthew A Ciorba
Journal:  Transl Res       Date:  2015-08-03       Impact factor: 7.012

2.  Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas.

Authors:  Jinzhong Liu; Zhenfeng Li; Jing Cui; Gang Xu; Guanglin Cui
Journal:  Tumour Biol       Date:  2011-12-02

3.  Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers.

Authors:  Guanglin Cui; Can Li; Gang Xu; Zhenglu Sun; Li Zhu; Zhengfen Li; Wei Zheng; Junling Li; Aping Yuan
Journal:  Pathol Oncol Res       Date:  2017-05-03       Impact factor: 3.201

4.  Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.

Authors:  Jin Ye; Hui Liu; Yanming Hu; Peng Li; Gehua Zhang; Yuan Li
Journal:  Virchows Arch       Date:  2012-11-20       Impact factor: 4.064

5.  Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

Authors:  Ben C Creelan; Scott Antonia; Gerold Bepler; Timothy J Garrett; George R Simon; Hatem H Soliman
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

6.  Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma.

Authors:  Ge Zhang; Wan-Li Liu; Lin Zhang; Jun-Ye Wang; Miao-Huan Kuang; Peng Liu; Yue-Hao Lin; Shu-Qin Dai; Jun Du
Journal:  Clin Dev Immunol       Date:  2011-10-13

7.  IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease.

Authors:  Robert Sucher; Katharina Kurz; Guenter Weiss; Raimund Margreiter; Dietmar Fuchs; Gerald Brandacher
Journal:  Int J Tryptophan Res       Date:  2010-06-10

8.  The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy.

Authors:  Yuan Wang; Guo-Fang Hu; Zhe-Hai Wang
Journal:  Onco Targets Ther       Date:  2017-07-19       Impact factor: 4.147

9.  Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Jiaqi Huang; Alison M Mondul; Stephanie J Weinstein; Stella Koutros; Andriy Derkach; Edward Karoly; Joshua N Sampson; Steven C Moore; Sonja I Berndt; Demetrius Albanes
Journal:  Br J Cancer       Date:  2016-09-27       Impact factor: 7.640

10.  A systematic review of metabolomic profiling of gastric cancer and esophageal cancer.

Authors:  Sha Huang; Yang Guo; Zhexuan Li; Yang Zhang; Tong Zhou; Weicheng You; Kaifeng Pan; Wenqing Li
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.